COMUNICADO: /C O R R E C T I O N -- Bristol-Myers Squibb and AstraZeneca/

Actualizado 04/03/2011 12:02:21 CET


- in combination with metformin, when metformin alone, with diet and
exercise, does not provide adequate glycaemic control;
- in combination with a sulphonylurea, when sulphonylurea alone, with
diet and exercise, does not provide adequate glycaemic control in
patients for whom use of metformin is considered inappropriate; or
- in combination with a thiazolidinedione, when the thiazolidinedione
alone, with diet and exercise, does not provide adequate glycaemic
control in patients for whom use of a thiazolidinedione is considered
appropriate

ONGLYZA is currently not indicated in combination with insulin therapy.

Please see the Summary of Product Characteristics for the full prescribing information.

Bristol-Myers Squibb and AstraZeneca Collaboration

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialise select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treatment of type 2 diabetes.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: http://www.astrazeneca.com.

ONGLYZA is a registered trademark of the Bristol-Myers Squibb Company.

Contacts:

Media: Carmel Hogan, Bristol-Myers Squibb, +33-158-836-555, carmel.hogan@bms.com

Jim Minnick, AstraZeneca, +1-302-885-5135, jim.minnick@astrazeneca.com

Investors: John Elicker, Bristol-Myers Squibb, +1-609-252-4611, john.elicker@bms.com

Karl Hard, AstraZeneca, +44-20-7604-8123, karl.j.hard@astrazeneca.com

CONTACT: Contacts: Media: Carmel Hogan, Bristol-Myers Squibb,+33-158-836-555, carmel.hogan@bms.com; Jim Minnick, AstraZeneca,+1-302-885-5135, jim.minnick@astrazeneca.com; Investors: John Elicker,Bristol-Myers Squibb, +1-609-252-4611,john.elicker@bms.com; Karl Hard, AstraZeneca, +44-20-7604-8123,karl.j.hard@astrazeneca.com

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación